GlobalGov › Germany › Pharmaceuticals › Solicitation

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-39 - Epoetin beta

Health, Health, Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

January 30, 2028
Response Due
Active
Status

About this record

The issuing agency did not publish a description for this notice. The full record as GlobalGov received it is below.

This Germany Pharmaceuticals opportunity is one most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHealth, Health, Health
CountryGermany
CategoryPharmaceuticals
PublishedDecember 04, 2025
Procurement stageActive solicitation
Response dueJanuary 30, 2028
StatusOpen — accepting responses
Original languageSwedish — members read it in their own language
Official sourceView original notice
Last verifiedSeptember 27, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Germany market overview →Pharmaceuticals tenders in Germany →Browse all categories →

Related Opportunities in Germany

Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Amifampridin, ATC N07XX05 für die Zeit 01.09.2025 - 31.08.2027 (zzgl. Verlängerungsoption 1x12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Estradiol + Dienogest, ATC G03AB08 für die Zeit 01.03.2026 - 29.02.2028 (zzgl. Verlängerungsoption 1x12 Mon)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Mepolizumab, (OBO) ATC R03DX09 für die Zeit 01.02.2025 - 31.01.2027
Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for the active ingredient rilpivirine, ATC J05AG05, for the period 01.07.2025 - 30.06.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Haloperidol (ausschließlich Injektionslösung), ATC N05AD01 für die Zeit 01.12.2025 - 30.11.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Edoxaban, ATC B01AF03 für die Zeit 01.04.2025 - 31.03.2026 (zzgl. Verlängerungsoption 1 x 12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Lenograstim, ATC L03AA10 für die Zeit 01.11.2025 - 31.10.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Erythropoietin, ATC B03XA01 für die Zeit 01.06.2025 - 31.05.2027 (zzgl. Verlängerungsoption 1x12 Monate)

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.